Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$1,012.82 USD

1,012.82
1,071,783

-1.77 (-0.17%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $1,012.36 -0.46 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Kodiak Sciences (KOD) Q1 Loss Widens, Eye Candidate in Focus

Kodiak Sciences (KOD) reports wider-than-expected loss in the first quarter of 2022. Focus is on lead candidate, KSI-301, being developed for treating various retinal vascular diseases.

Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1

Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat

Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

Ultragenyx's (RARE) Q1 Earnings & Revenues Miss Estimates

Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.

Regeneron (REGN) Q1 Earnings Beat, COVID Antibody Sales Affected

Regeneron (REGN) beats on Q1 earnings and sales record year-over-year growth on the solid performance of Dupixent and Eylea.

Regeneron (REGN) Q1 Earnings and Revenues Beat Estimates

Regeneron (REGN) delivered earnings and revenue surprises of 22.63% and 9.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

Will Eylea, Dupixent Buoy Regeneron's (REGN) Q1 Earnings?

Regeneron's (REGN) first-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent.

The Zacks Analyst Blog Highlights Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen

Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen have been included in this Analyst Blog.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue View

Alnylam's (ALNY) earnings and sales fall shy of estimates in the first quarter of 2022. The company cuts 2022 guidance for net product revenues. Shares down.

Indrajit Bandyopadhyay headshot

5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates

Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.

Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales Rise

Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines. Consumer healthcare sales remain strong.

Regeneron (REGN) Expected to Beat Earnings Estimates: Should You Buy?

Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regeneron (REGN) Gains But Lags Market: What You Should Know

Regeneron (REGN) closed at $690.33 in the latest trading session, marking a +0.33% move from the prior day.

Roche's (RHHBY) Q1 Sales Grow on COVID-19 Tests, New Drugs

Roche (RHHBY) performance in the first quarter was encouraging, driven by demand for COVID-19 tests and contribution from newer drugs.

Regeneron (REGN) Dips More Than Broader Markets: What You Should Know

Regeneron (REGN) closed at $706.11 in the latest trading session, marking a -1.88% move from the prior day.

Biotech Stock Roundup: NKTR Plunges on Deal Termination, REGN Offers Update & More

Regulatory and pipeline updates from Nektar (NKTR) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

Regeneron (REGN) to Buy Checkmate Pharmaceuticals for $250M

Regeneron (REGN) is set to acquire Checkmate Pharmaceuticals for $250 million to broaden its portfolio of diverse immuno-oncology candidates.

Amgen's (AMGN) Stelara Biosimilar Meets Psoriasis Study Goal

Initial data from a late-stage study comparing Amgen's (AMGN) Stelara biosimilar candidate with the original Stelara drug showed no clinically meaningful differences in treating plaque psoriasis.

Regeneron (REGN) REGEN-COV BLA Review Extended by 3 Months

Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.

Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?

Regeneron (REGN) gains 17% YTD on the back of Eylea, Dupixent and good pipeline progress.

Zacks Investment Ideas feature highlights: Regeneron and Bristol-Myers Squibb

Regeneron and Bristol-Myers Squibb are part of today's Investment Idea article.